How many months does a standard course of treatment with bedaquiline take?

Bedaquiline (Bedaquiline) is an important drug for the treatment of multidrug-resistant tuberculosis (MDR-TB). Its standard treatment cycle is usually 6 months according to internationally recognized guidelines, which is about 24 weeks. Throughout the course of treatment, bedaquiline is not used alone, but is combined with several other anti-tuberculosis drugs to form a multi-drug treatment regimen to reduce the further evolution and spread of drug-resistant bacteria. It is often used as the core drug in the intensive phase of treatment, taken once daily for the first two weeks, then three times weekly until the end of week 24. The dosing regimen designed in this way aims to maintain drug concentration while minimizing the accumulation of side effects and improving patient compliance.

The reason why bedaquiline is restricted to use within 6 months is closely related to its pharmacokinetic properties. Its half-life in the human body is as long as several months, which means that even after stopping the drug, certain active ingredients are still retained in the body and continue to act on Mycobacterium tuberculosis for a long time. This feature is both its therapeutic advantage and limits its safety for long-term use. Prolonging the course of treatment may increase the risk of cardiac adverse reactions such as QT interval prolongation, especially when combining linezolid and fluoroquinolones.

It needs to be emphasized that the use of bedaquiline must strictly follow the doctor's individualized treatment plan. Because factors such as the infection type, drug resistance spectrum, underlying diseases, and drug interactions of tuberculosis patients may affect treatment design. For some patients with extensive drug resistance or poor response to treatment, doctors sometimes moderately extend the use time after comprehensive weighing, but this adjustment needs to be based on continuous monitoring of QT interval, electrolyte levels, liver and kidney function and other indicators.

In general, the standard treatment course of bedaquiline is6 months, which has been widely recognized by the World Health Organization and national guidelines as one of the current basic regimens for the treatment of drug-resistant tuberculosis.

Reference materials:https://en.wikipedia.org/wiki/Bedaquiline